CBO Predicts Drug Pricing Bill Would Lead To Higher Launch Prices

By John Wilkerson / August 5, 2022 at 7:08 PM
Drug companies will hike launch prices to offset losses from price-inflation rebates and Medicare price negotiation, the Congressional Budget Office told Sen. Lindsey Graham (R-SC) Thursday (Aug. 4), though inflation rebates are the main reason for higher projected launch prices. Those higher prices will primarily hurt state Medicaid programs and Medicare Part B, but eventually slower price growth would attenuate the effect of higher launch prices. Graham asked CBO how Senate Democrats’ drug pricing bill would affect launch prices for...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.